11.18.14
Integra LifeSciences Holdings Corp. has rolled out, in a limited release, a new orthobiologic implant. The demineralized bone matrix (DBM) Strip implant primarily is used primarily for posterior lumbar fusion, a surgical procedure intended to promote bone fusion along the posterior elements of the spine.
The product will be distributed by Integra's IsoTis OrthoBiologics subsidiary. It was featured during the recent North American Spine Society (NASS) annual meeting held in San Francisco, Calif.
Available in two forms, the Integra Shaped Strip and Integra Pocket Strip are 100 percent human allograft, providing a natural biologic scaffold with verified osteoinductive (bone growth) potential, according to the company. The implant features a deep recess designed to accommodate placement of additional graft material. When hydrated, the graft is pliable, maintains integrity upon irrigation, and can be contoured to varying patient anatomy.
"We're very excited to add these new implants to Integra's orthobiologic product portfolio. This not only addresses an identified market need, but is Integra's first DBM implant designed for a specific surgical procedure. The new implant also expands our biologics footprint and strengthens our overall position in the spine market," said John Winge, vice president of Integra’s U.S. spine sales.
Plainsboro, N.J.-based Integra LifeSciences makes specialty surgical solutions, orthopedics and tissue technologies, and spine hardware and orthobiologics.
The company recently announced plans to spin off its spine business to create a new publicly traded company called SeaSpine—the name of a former acquisition—focused on spine hardware and orthobiologics.
The product will be distributed by Integra's IsoTis OrthoBiologics subsidiary. It was featured during the recent North American Spine Society (NASS) annual meeting held in San Francisco, Calif.
Available in two forms, the Integra Shaped Strip and Integra Pocket Strip are 100 percent human allograft, providing a natural biologic scaffold with verified osteoinductive (bone growth) potential, according to the company. The implant features a deep recess designed to accommodate placement of additional graft material. When hydrated, the graft is pliable, maintains integrity upon irrigation, and can be contoured to varying patient anatomy.
"We're very excited to add these new implants to Integra's orthobiologic product portfolio. This not only addresses an identified market need, but is Integra's first DBM implant designed for a specific surgical procedure. The new implant also expands our biologics footprint and strengthens our overall position in the spine market," said John Winge, vice president of Integra’s U.S. spine sales.
Plainsboro, N.J.-based Integra LifeSciences makes specialty surgical solutions, orthopedics and tissue technologies, and spine hardware and orthobiologics.
The company recently announced plans to spin off its spine business to create a new publicly traded company called SeaSpine—the name of a former acquisition—focused on spine hardware and orthobiologics.